product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Human NKG2D/CD314 PE-conjugated Antibody
catalog :
FAB139P-025
quantity :
25 Tests (also 100 Tests)
price :
129 USD
clonality :
monoclonal
host :
mouse
conjugate :
PE
clone name :
149810
reactivity :
human
application :
immunocytochemistry, flow cytometry
more info or order :
R&D Systems product webpage
citations: 33
Reference
Seier S, Bashiri Dezfouli A, Lennartz P, Pockley A, Klein H, Multhoff G. Elevated Levels of Circulating Hsp70 and an Increased Prevalence of CD94+/CD69+ NK Cells Is Predictive for Advanced Stage Non-Small Cell Lung Cancer. Cancers (Basel). 2022;14: pubmed publisher
Chimienti R, Baccega T, Torchio S, Manenti F, Pellegrini S, Cospito A, et al. Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for β cell replacement. Cell Rep. 2022;40:111423 pubmed publisher
Lobinger D, Gempt J, Sievert W, Barz M, Schmitt S, Nguyen H, et al. Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients. Front Mol Biosci. 2021;8:669366 pubmed publisher
De Sanctis J, Dumut D, Radzioch D, Hajduch M. Functionally Relevant Differences in Plasma Fatty Acid Composition and Expression of Cytotoxic and Inhibitory NK Cell Receptors between Healthy Young and Healthy Elder Adults. Nutrients. 2020;12: pubmed publisher
Xu H. Expressions of natural cytotoxicity receptor, NKG2D and NKG2D ligands in endometriosis. J Reprod Immunol. 2019;136:102615 pubmed publisher
Mallmann Gottschalk N, Sax Y, Kimmig R, Lang S, Brandau S. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. Int J Mol Sci. 2019;20: pubmed publisher
Oh E, Min B, Li Y, Lian C, Hong J, Park G, et al. Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect). Cancers (Basel). 2019;11: pubmed publisher
Bhat J, Dubin S, Dananberg A, Quabius E, Fritsch J, Dowds C, et al. Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells. Front Immunol. 2019;10:569 pubmed publisher
Tanaka Y, Nakazawa T, Nakamura M, Nishimura F, Matsuda R, Omoto K, et al. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PLoS ONE. 2019;14:e0212455 pubmed publisher
Yu H, Chen W, Li C, Lin D, Liu J, Yang Z, et al. Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy. Exp Ther Med. 2017;14:5678-5686 pubmed publisher
Shi J, Zhao J, Zhang X, Cheng Y, Hu J, Li Y, et al. Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients. Sci Rep. 2017;7:44544 pubmed publisher
Gill U, Peppa D, Micco L, Singh H, Carey I, Foster G, et al. Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLoS Pathog. 2016;12:e1005788 pubmed publisher
Lee S, Kang W, Yoon Y, Jin J, Song H, Her J, et al. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain. BMC Cancer. 2015;15:1011 pubmed publisher
Picardi A, Mengarelli A, Marino M, Gallo E, Benevolo M, Pescarmona E, et al. Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. J Exp Clin Cancer Res. 2015;34:98 pubmed publisher
Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, et al. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PLoS ONE. 2015;10:e0134568 pubmed publisher
Kruse V, Hamann C, Monecke S, Cyganek L, Elsner L, Hübscher D, et al. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1. PLoS ONE. 2015;10:e0125544 pubmed publisher
Schilling D, Kühnel A, Tetzlaff F, Konrad S, Multhoff G. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells. Cancer Immunol Immunother. 2015;64:599-608 pubmed publisher
Morisaki T, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, et al. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res. 2014;34:4529-38 pubmed
Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M, et al. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro. Anticancer Res. 2014;34:4509-19 pubmed
Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, et al. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Eur J Immunol. 2014;44:2761-70 pubmed publisher
Hu X, Jiang Y, Li X, Gao Y, Guo X, Chi X, et al. Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection. J Interferon Cytokine Res. 2014;34:366-75 pubmed publisher
Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, et al. Natural killer cells are characterized by the concomitantly increased interferon-? and cytotoxicity in acute resolved hepatitis B patients. PLoS ONE. 2012;7:e49135 pubmed publisher
Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, et al. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res. 2011;31:2505-10 pubmed
Qin H, Lee I, Panagiotopoulos C, Wang X, Chu A, Utz P, et al. Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling. Diabetes. 2011;60:857-66 pubmed publisher
Llinàs L, Lázaro A, de Salort J, Matesanz Isabel J, Sintes J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett. 2011;134:113-21 pubmed publisher
Clemente A, Cambra A, Munoz Saá I, Crespí C, Pallares L, Juan A, et al. Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Behçet's disease patients and healthy controls. Immunol Lett. 2010;129:57-63 pubmed publisher
Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer. 2009;125:212-21 pubmed publisher
Teixeira Carvalho A, Fujiwara R, Stemmy E, Olive D, Damsker J, Loukas A, et al. Binding of excreted and/or secreted products of adult hookworms to human NK cells in Necator americanus-infected individuals from Brazil. Infect Immun. 2008;76:5810-6 pubmed publisher
Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129:428-37 pubmed publisher
Kwong K, Baskar S, Zhang H, Mackall C, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol. 2008;384:1143-56 pubmed publisher
Manaster I, Mizrahi S, Goldman Wohl D, Sela H, Stern Ginossar N, Lankry D, et al. Endometrial NK cells are special immature cells that await pregnancy. J Immunol. 2008;181:1869-76 pubmed
Kim Y, Han M, Broxmeyer H. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells. Blood. 2008;111:1378-86 pubmed
Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol. 2005;174:1338-47 pubmed
product information
brand :
R&D Systems
master code :
FAB139P
SKU :
FAB139P-025
product name :
Human NKG2D/CD314 PE-conjugated Antibody
unit size :
25 Tests (also 100 Tests)
seo description :
The Human NKG2D/CD314 PE-conjugated Antibody from R&D Systems is a mouse monoclonal antibody to NKG2D/CD314. This antibody reacts with human. The Human NKG2D/CD314 PE-conjugated Antibody has been validated for the following applications: Flow Cytometry,Immunocytochemistry.
target :
NKG2D/CD314
category :
Primary Antibodies
buffer :
Supplied in a saline solution containing BSA and Sodium Azide.
clonality :
Monoclonal
clone :
149810
conjugate :
Phycoerythrin
dilution :
Flow Cytometry 10 uL/10^6 cells
host :
Mouse
immunogen :
BaF3 mouse pro-B cell line transfected with human NKG2D/CD314
isotype :
IgG1
purity :
Protein A or G purified from hybridoma culture supernatant
species :
Human
specificity :
Detects human NKG2D/CD314 in Western blots.
gene symbol :
KLRK1
top caption :
Detection of NKG2D/CD314 antibody in Human PBMCs gated on CD3-cells antibody by Flow Cytometry.
applications :
Flow Cytometry,Immunocytochemistry
extended description :
Clone 149810 was used by HLDA to establish CD designation
USD :
129 USD
product details :
Clone 149810 was used by HLDA to establish CD designation
alt names :
CD314, CD314 antigen, D12S2489E, FLJ17759, FLJ75772, Killer cell lectin-like receptor subfamily K member 1, killer cell lectin-like receptor subfamily K, member 1, KLR, KLRK1, NK cell receptor D, NKG2-D, NKG2-D type II integral membrane protein, NKG2-D-activating NK receptor, NKG2DDNA segment on chromosome 12 (unique) 2489 expressed sequence
storage :
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 ░C as supplied.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.